Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
NiKang Therapeutics, Inc.
NiKang Therapeutics, Inc.
Thomas Jefferson University
Hoffmann-La Roche
Gachon University Gil Medical Center
Daiichi Sankyo
Dendreon
Assistance Publique - Hôpitaux de Paris
Assistance Publique - Hôpitaux de Paris